Shares in AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs, according to the latest figures. The move reflects a broader rotation by investors toward defensive sectors as technology stocks face a selloff.
The shift underscores changing investor sentiment, with money flowing out of growth-focused technology companies and into more stable pharmaceutical businesses.